



ATOPIC ECZEMA/DERMATITIS

MYCOPHENOLATE MOFETIL THERAPY IN ADULT PATIENTS WITH RECALCITRANT ATOPIC DERMATITIS.

David Dias-polak⁽¹⁾ - Reuven Bergman⁽²⁾ - Emily Avitan-hersh⁽²⁾

Rambam Health Care Campus And The Bruce Rappaport Faculty Of Medicine, Technion2, Haifa, Israel, Dermatology, Haifa, Israel⁽¹⁾ - Rambam Health Care Campus And The Bruce Rappaport Faculty Of Medicine, Technion, Haifa, Israel, Dermatology, Haifa, Israel⁽²⁾

BACKGROUND: Patients with severe atopic dermatitis (AD) may require potent immunosuppressive therapy to control their disease. Mycophenolate mofetil (MMF) has been suggested as a safe and effective drug in these cases.

OBJECTIVES: To investigate effectiveness and tolerability of oral MMF in adult patients with severe recalcitrant AD.

METHODS: During the years 2010-2017 oral MMF 2-3 g/day was administered to adult patients with severe recalcitrant AD who failed other major systemic drugs, or where other drugs, including cyclosporine (CSA), methotrexate, and azathioprine, were contraindicated.

RESULTS: Of 9 consecutive adult patients, 4 (44%) responded completely, 2 (22%) had partial response, and 3 (33%) did not respond at all. The MMF therapy was continued for 5-36 months (average 21 months) without major side effects.

CONCLUSIONS: Oral MMF may be an effective drug in AD. Due to its good safety profile, it may be recommended as a first-line systemic therapy, or successive to CSA in the long term.

